Details of the Drug
General Information of Drug (ID: DMV6WC4)
Drug Name |
4-phenyl-1,2,3,6-tetrahydropyridine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
4-Phenyl-1,2,3,6-tetrahydropyridine; 10338-69-9; 4-Phenyl-1,2,3,6-tetrahydro-pyridine; 1,2,3,6-tetrahydro-4-phenyl-pyridine; 1,2,3,6-Tetrahydro-4-phenylpyridine; Pyridine, 1,2,3,6-tetrahydro-4-phenyl-; CHEMBL6224; OMPXTQYWYRWWPH-UHFFFAOYSA-N; 4-phenyl-1,2,3,6-tetrahydro pyridine; Oprea1_874761; NSC 54451; AC1Q1IN6; AC1L33NE; AC1Q1GX2; SCHEMBL415545; DTXSID2065040; CTK4A2038; MolPort-001-794-494; 43064-12-6 (hydrochloride); ZINC1295150; NSC54451; 4-Phenyl-1,3,6-tetrahydropyridine; STK535809; NSC-54451; BDBM50036718; BBL027886
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 159.23 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||